Astria Therapeutics (NASDAQ:ATXS – Get Free Report) posted its earnings results on Monday. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05), Yahoo Finance reports.
Astria Therapeutics Trading Up 4.5 %
ATXS stock traded up $0.44 during mid-day trading on Tuesday, reaching $10.20. The company’s stock had a trading volume of 90,888 shares, compared to its average volume of 740,466. Astria Therapeutics has a fifty-two week low of $4.26 and a fifty-two week high of $16.90. The stock has a market cap of $560.11 million, a PE ratio of -4.21 and a beta of 0.73. The company’s 50 day moving average is $10.03 and its two-hundred day moving average is $11.38.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on ATXS. Wedbush reissued an “outperform” rating and set a $22.00 price objective on shares of Astria Therapeutics in a report on Tuesday. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research note on Tuesday. Oppenheimer boosted their target price on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, TD Cowen initiated coverage on shares of Astria Therapeutics in a research report on Monday, July 29th. They issued a “buy” rating and a $35.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Astria Therapeutics presently has a consensus rating of “Buy” and an average target price of $25.20.
About Astria Therapeutics
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
Read More
- Five stocks we like better than Astria Therapeutics
- How to Use the MarketBeat Dividend Calculator
- Market Turbulence: Time to Snap Up Magnificent Seven Stocks?
- Breakout Stocks: What They Are and How to Identify Them
- Buy the Dip in Home Depot, But Wait for It to Bottom First
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Micron Stock Just Got Its Most Bullish Update Of The Year
Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
